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Abstract
Background: Both overproduction of nitric oxide (NO) and oxidative injury of cardiovascular and
pulmonary systems contribute to fatal cardiovascular depression during endotoxemia. We investigated in
the present study the relative contribution of oxidative stress and NO to cardiovascular depression during
different stages of endotoxemia, and delineated their roles in cardiovascular protective effects of a
commonly used anesthetic propofol during endotoxemia.
Methods: Experimental endotoxemia was induced by systemic injection of E. coli lipopolysaccharide (LPS,
15 mg/kg) to Sprague-Dawley rats that were maintained under propofol (15 or 30 mg/kg/h, i.v.) anesthesia.
Mean systemic arterial pressure (MSAP) and heart rate (HR) were monitored for 6 h after the endotoxin.
Tissue level of NO was measured by chemical reduction-linked chemiluminescence and oxidative burst
activity was determined using dihydroethidium method. Expression of NO synthase (NOS) was
determined by immunoblotting. The Scheffé multiple range test was used for post hoc statistical analysis.
Results: Systemic injection of LPS (15 mg/kg) induced biphasic decreases in MSAP and HR. In the heart,
lung and aorta, an abrupt increase in lipid peroxidation, our experimental index of oxidative tissue injury,
was detected in early stage and sustained during late stage cardiovascular depression. LPS injection, on the
other hand, induced a gradual increase in tissue nitrite and nitrate levels in the same organs that peaked
during late stage endotoxemia. Propofol infusion (15 or 30 mg/kg/h, i.v.) significantly attenuated lipid
peroxidation in the heart, lung and aorta during early and late stage endotoxemia. High dose (30 mg/kg/h,
i.v.) propofol also reversed the LPS-induced inducible NO synthas e  ( i N O S )  u p r e g u l a t i o n  a n d  N O
production in the aorta, alongside a significant amelioration of late stage cardiovascular depression and
increase in survival time during endotoxemia.
Conclusion: Together these results suggest that oxidative injury and NO may play a differential role in
LPS-induced cardiovascular depression. Oxidative tissue injury is associated with both early and late stage;
whereas NO is engaged primarily in late stage cardiovascular depression. Moreover, propofol anesthesia
may protect against fatal cardiovascular depression during endotoxemia by attenuating the late stage NO
surge in the aorta, possibly via inhibition of iNOS upregulation by the endotoxin.
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Background
Sepsis poses a major clinical problem in management of
patients in the intensive care units. Sepsis carries a high
mortality rate and is the leading cause of death in critically
ill patients [1,2]. Most common cause of sepsis in human
is a contamination of the blood with bacteria. Endotoxins
of Gram-negative bacteria induce systemic inflammatory
responses characterized by induction of pro-inflamma-
tory cytokines, fever, hypotension and intravascular coag-
ulation [3]. Uncontrolled inflammatory responses to
bacteria infection result in collapse of cardiovascular func-
tions, leading to multiple organ failure and mortality of
sepsis [4,5]. Diverse molecular mechanisms of inflamma-
tion and cellular damage contribute to cardiovascular
depression during sepsis, of which overt production of
nitric oxide (NO) and oxidative stress of a heightened tis-
sue level of the reactive oxygen species (ROS) have
attracted intensive research because of their intimate roles
in regulation of cardiovascular and pulmonary functions
[6-8]. Overproduction of NO accounts in part for endo-
toxin-induced vascular hyporactivity and hypotension
[9]. NO is also a key molecule responsible for acute pul-
monary injury during endotoxemia [10,11]. ROS, in par-
ticular superoxide anion (O2
•-), mediates the reduced
vasoconstriction, impaired bronchodilation and endothe-
lial dysfunction in endotoxemia [8,12]. O2
￿- is also a
proinflammatory mediator that is involved in recruitment
of neutrophils [13,14], formation of chemotactic factors
[13,15], initiation of lipid peroxidation [16], and release
of proinflammatory cytokines [11,17] during endotox-
emia. Although a vast amount of evidence supports NO
and O2
￿- in the pathological sequelae of endotoxemia, rel-
ative contribution of these two molecules to cardiovascu-
lar depression during different stages of endotoxemia has
not been fully defined.
Propofol (2,6-diisopropylphenol) has gained common
application in the intensive care units for sedation and
hypnosis purposes bacause of its pharmacokinetics of
rapid uptake and elimination from the central nervous
system and short duration of action [18]. Accumulating
evidence suggests that propofol possesses nonsedative
protective effects against endotoxemia. Propofol exerts
anti-inflammatory effects [19,20], inhibits platelet aggre-
gation [21], suppresses neutrophil infiltartion [21,22],
and improves endothelial dysfunction [23] in animal
models of endotoxemia and in patients of sepsis. Propo-
fol also inhibits oxidative damage in vascular smooth
muscle cells [24]and protects vascular endothelium from
oxidative injury [23]. In addition, it decreases inducible
NO synthase (iNOS) activity, and inhibits NO production
during endotoxemia [19,20,22,23]. All these protective
effects of propofol have been reported to be beneficial to
endotoxemia. Significance of the protective effects of pro-
pofol during different stages of endotoxemia, however,
remains largely unexplored.
Endotoxemia induced by intravenous injection of E. coli
lipopolysaccharide (LPS) into the laboratory animals has
been used to replicate the pathophysiological events of
septic shock in patients [25]. In the present study, we used
different dose of propofol (15 or 30 mg/kg/h) to examine
whether the anesthetic may possess differential protective
effect against cardiovascular depression during different
stages of LPS-induced endotoxemia by exerting differen-
tial protective effects against oxidative stress and overpro-
duction of NO in cardiovascular and pulmonary systems.
Methods
Animals
Male adult (10–12 week old) Sprague-Dawley rats (250–
340 g, n = 315), purchased from BioLASCO Co., Taiwan,
were used. They were housed in an animal room under
temperature control (24 ± 0.5°C) and 12-h light-dark
(08:00 to 20:00) cycle. Standard laboratory rat chow (PMI
Nutrition International, Brentwood, MO, USA) and tap
water were available ad libitum. All animals were allowed
to acclimatize for at least 7 days prior to experimental
manipulations. All experimental procedures were carried
out in compliance with the guidelines of our institutional
animal care committee, and were in accordance with the
Guide for the Care and Use of Laboratory Animals as
adopted and promulgated by the U.S. National Institutes
of Health.
General preparation
Rats were anesthetized initially with pentobarbital
sodium (50 mg/kg, ip) to perform preparatory surgery
[26], which included intubation of the trachea to facilitate
ventilation and cannulation of the femoral artery and vein
for systemic arterial pressure (SAP) measurement and
drug administration. All surgical procedures were per-
formed under a surgical plane of anesthesia as indicated
by the absence of withdrawal reflex to hindpaw pinch.
Pulsatile or mean SAP (MSAP) and heart rate (HR) were
recorded on a polygraph (Gould, Valley View, OH, USA).
Animals were mechanically ventilated to maintain an
end-tidal CO2 to be within 4 to 5%, as monitored by a
capnograph (Datex Normocap, Helsinki, Finland). All
data were collected from animals with a maintained rectal
temperature of 37 ± 0.5°C. At the end of each experiment,
rats were killed with intravenous injection of an overdose
of pentobarbital sodium (100 mg/kg).
Induction of experimental endotoxemia
Experimental endotoxemia was induced by intravenous
infusion (50 μl/min for 3 min) of Escherichia coli. lipopol-
ysaccharide (LPS, 15 mg/kg, serotype 0111:B4; Sigma-
Aldrich, St. Louis, MO, USA) to the anesthetized animalsJournal of Biomedical Science 2009, 16:8 http://www.jbiomedsci.com/content/16/1/8
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[26,27]. Infusion of the same amount of 0.9% saline
served as vehicle and volume control. The temporal
changes in mean SAP and HR were routinely followed for
8 h. Total survival time and survival rate, using 8 h postin-
fusion time interval as the cut-off time, were also
recorded.
Protein extraction and Western blot analysis
Extraction of total protein from the heart, lung or aorta
was carried out as detailed previously [27]. In brief, tissue
was lysed with ice-cold lysis buffer. Protease inhibitors
(10 μg/ml aprotinin, 10 μg/ml leupeptin and 20 μg/ml
phenylmethylsulfonyl fluoride) and phosphatase inhibi-
tors (2 mM NaF, 1 mM sodium orthovanadate, 10 mM
sodium pyrophosphate) were included in the lysis buffer
to prevent protein degradation. Solubilized proteins were
centrifugated at 20000 g at 4°C for 15 min, and proteins
in the supernatant were quantified by the Bradford assay
with a protein assay kit (Bio-Rad, Hercules, CA, USA).
Proteins (50 to 100 μg) were separated using 10% SDS-
PAGE and transferred to PVDF membrane. The primary
antiserum used for Western blot analysis included a rabbit
polyclonal antiserum against neuronal NOS (nNOS),
inducible NOS (iNOS), endothelial NOS (eNOS)
(1:1000; BD Biosciences, San Jose, CA, USA) or α-tubulin
(1:10000; Sigma-Aldrich). This was followed by incuba-
tion with horseradish peroxidase-conjugated goat anti-
rabbit IgG (1:10000; Jackson Immunoresearch Laborato-
ries, West Grove, PA, USA). Specific antibody-antigen
complex was detected using an enhanced chemilumines-
cence Western Blot detection system (Perkin-Elmer Life
Sciences, Boston, MA). The amount of detected protein
was quantified by Photo-Print Plus software (ETS Vilber-
Lourmat, France), and was expressed as the ratio to α-
tubulin protein, which served as the internal control to
demonstrate equal loading of proteins.
Nitric oxide measurement
The tissue concentration of total nitrate and nitrite (NOx)
was measured by chemical reduction-linked chemilumi-
nescence using a purge system nitric oxide analyzer (Siev-
ers NOA 280™, Boulder, CO, USA). Tissue homogenates
of heart, lung or aorta were mixed in 0.4 N NaOH (0.3 ml)
and were incubated at room temperature for 5 min. A 5%
ZnSO4 (0.3 ml) was then added to the mixture and was
incubated for another 5 min at room temperature. The
mixture was centrifuged 3700 g for 20 min at 4°C, and the
supernatant was injected into a purge vessel to react with
the VCl3/HCl reagent, which converted nitrites and
nitrates into NO. The amount of NOx in the test sample
was determined by interpolation of the result into the
standard curve. All assays were performed in triplicate and
expressed as nmol/mg protein.
Lipid peroxidation assay
Lipid peroxidation was quantified by determining
malondialdehyde (MDA) level in the heart, lung or aorta
via the thiobarbituric acid reacting substances (TBARS)
[28]. The quantification of TBARS was determined by
comparing the absorption at 532 nm to the standard
curve of MDA equivalents generated by acid catalyzed
hydrolysis of 1,1,3,3 tetramethoxypropane, and was
expressed as nmol/mg protein.
Oxidative burst activity
The extent of intracellular reactive oxygen species produc-
tion was determined using a whole-blood assay in freshly
drawn heparinized blood. The oxidative burst of poly-
morphonuclear leukocytes (PMN) or lymphocytes was
determined using dihydroethidium (DHE) method. In
brief, after oxidization step (30 min at 37°C) in which the
non-fluorescent substrate, DHE, is taken up by the blood
cells and converted into a fluorescent compound (ethid-
ium) through respiratory burst metabolites, the citrated
whole blood was lying, followed by white blood cell
washing, and re-suspension in ice-cold PBS. The blood
cell samples were gated and analyzed with a laser flow
cytometer (FACScan/Lysis II, Becton Dickinson, Heidel-
berg, Germany) using blue/green excitation light (488 nm
Argon Laser). Populations of monocytes and neutrophils
were separately by electronic gating in the forward scatter
(FSC)/side scatter (SSC) dot plot, and was measured and
quantified in arbitrary units of 10,000 events.
Experimental protocols
After a 30-min period of stable hemodynamics following
the completion of general preparation, blood samples
were collected from tail artery for baseline measurements.
Animals received thereafter continuous intravenous infu-
sion of propofol (AstraZeneca, Maccelesfield Cheshire,
UK; 15 or 30 mg/kg/h) and were randomly assigned to
receive LPS (endotoxemia group) or saline (control
group) injection 60 min after propofol infusion. At 1, 4 or
6 h after the endotoxin, tissue (heart, lung and aorta) sam-
ples were harvested for analysis of NOS protein expres-
sion, NOx content, and lipid peroxidation. Blood samples
were collected for determination of PMN or lymphocyte
oxidative burst activity. This postinjection interval after
the endotoxin was selected to represent the early or late
phase endotoxemia, based on our previous reports
[26,27] in which different phases of endotoxemia were
characterized by changes in power density of the vasomo-
tor components of SAP spectrum. To confirm the effect of
propofol on LPS-evoked biochemical and hemodynamic
responses, LPS was injection to animals that were main-
tained under pentobarbital sodium (Sigma-Aldrich, St
Louis, MO; 15 mg/kg/h) anesthesia in a separate series of
experiments. In our pilot study we found that pentobarbi-Journal of Biomedical Science 2009, 16:8 http://www.jbiomedsci.com/content/16/1/8
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tal sodium (15 mg/kg/h) provided satisfactory anesthetic
maintenance similar to that by propofol (15 mg/kg/h).
Statistical analysis
All values are expressed as mean ± SEM. One-way or two-
way ANOVA with repeated measures was used, as appro-
priate, to assess group means. This was followed by the
Scheffé multiple range test for post hoc assessment of
individual means. A value of P < 0.05 was taken to indi-
cate statistical significance.
Results
Effect of propofol on cardiovascular depression during 
endotoxemia
Baseline mean systemic arterial pressure (MSAP) or heart
rate (HR) was comparable among the saline- or LPS-
treated animals that received continuous infusion of pro-
pofol (15 or 30 mg/kg/h) (Fig. 1). In consistent to our pre-
vious findings [26,27], intravenous injection of LPS (15
mg/kg) caused transient but significant decreases in MSAP
and HR, followed by partial recovery of the same hemo-
dynamic parameters and the second phase of hypotension
and bradycardia. The initial hypotension and bradycardia
lasted less than 1 h and the delayed phase cardiovascular
depression commenced approximately 3 h after the endo-
toxin. Compared to animals maintained under pentobar-
bital sodium (15 mg/kg/h) anesthesia, the LPS-induced
second phase cardiovascular depression was dose-
dependently blunted in those maintained under propofol
(15 or 30 mg/kg/h) anesthesia (Fig. 1). Infusion of propo-
fol or pentobarbital sodium alone, on the other hand,
evoked no significant effect on baseline MSAP or HR dur-
ing the 8-h observation period.
Effect of propofol on tissue lipid peroxidation during 
endotoxemia
The change in tissue MDA production was used in the
present study to reflect lipid peroxidation. While propofol
anesthesia (15 or 30 mg/kg/h) alone did not affect basal
level of MDA, the LPS-induced increase in MDA produc-
tion in the heart, lung or aorta was significantly amelio-
rated in animals that received propofol infusion at 30 mg/
kg/h (Fig. 2). This protective effect by propofol was
observed during initial (i.e., 1 h postinjection) and
delayed (i.e., 4 h postinjection) phases of endotoxemia.
Moreover, LPS-induced lipid peroxidation was almost
completely prevented in the lung of animal maintained
under propofol infusion at 30 mg/kg/h (Fig. 2). At 6 h
after LPS injection, protection by high dose (30 mg/kg/h)
propofol on the LPS-induced increases in tissue MDA pro-
duction in the heart (69.8 ± 7.3 nmol/mg protein, n = 6),
lung (63.8 ± 5.1 nmol/mg protein, n = 6) or aorta (89.0 ±
6.4 nmol/mg protein, n = 6) was diminished. Systemic
injection of LPS resulted in a grater increase in MDA pro-
duction detected at 4 h postinjection in the heart (144.9 ±
10.7 nmol/mg protein, n = 4), lung (138.6 ± 10.6 nmol/
mg protein, n = 4) or aorta (146.4 ± 11.6 nmol/mg pro-
tein, n = 4) of animals maintained under pentobarbital
sodium anesthesia. This anesthetic agent alone did not
affect basal level of MDA in the same tissues (heart: 25.9
± 4.8 nmol/mg protein, n = 4; Lung: 37.9 ± 6.4 nmol/mg
protein, n = 4; aorta: 60.4 ± 5.8 nmol/mg protein, n = 4).
Effect of propofol on oxidative respiratory burst of blood 
cells during endotoxemia
LPS treatment (15 mg/kg) also resulted in oxidative respi-
ratory burst of PMN and lymphocytes from the blood of
animals under propofol anesthesia (Fig. 3). Compared to
propofol anesthesia at 15 mg/kg/h, LPS-induced increase
in oxidative burst of PMN, but not lymphocytes, was sig-
nificantly reduced at 1 or 4 h after the endotoxin in ani-
mals that received propofol anesthesia at 30 mg/kg/h.
Propofol alone, at either dose, did not affect the ROS pro-
duction in PMN or lymphocytes after saline injection.
Effect of propofol on tissue nitric oxide concentration 
during endotoxemia
Compared with saline control, LPS treatment (15 mg/kg)
significantly increased NOx content in the heart, lung or
aorta, measured at 1 or 4 h after the endotoxin, in animals
under propofol anesthesia (15 or 30 mg/kg/h) (Fig. 4).
Similar results were obtained in the heart (130 ± 15 nmol/
mg protein, n = 4), lung (119 ± 11 nmol/mg protein, n =
4) or aorta (366 ± 23 nmol/mg protein, n = 4) 4 h after
systemic injection of LPS to animals maintained under
pentobarbital sodium anesthesia. The LPS-induced NOx
surges in the heart and lung during the initial and delayed
phases of endotoxemia were comparable in animals that
received propofol anesthesia at 15 or 30 mg/kg/h. At 6 h
after high dose (30 mg/kg, i.v.) propofol infusion, NOx
levels in the heart (152 ± 13 nmol/mg protein, n = 6) or
lung (118 ± 11 nmol/mg protein, n = 6) was comparable
to that detected in 1 or 4 h after LPS injection. The increase
in NOx content in the aorta during the delayed, but not
initial, phase of endotoxemia was discernibly blunted in
animals under propofol anesthesia at 30 mg/kg/h (Fig. 4).
This protection against NOx surge by high dose propofol
(270 ± 19 nmol/mg protein, n = 6) lasted for at least 6 h
after LPS injection. Propofol (Fig. 4) or pentobarbital
sodium infusion alone had no effect on tissue level of
NOx in the heart (39.8 ± 5.4 nmol/mg protein, n = 4),
lung (40.2 ± 4.3 nmol/mg protein, n = 4) or aorta (65.0 ±
6.5 nmol/mg protein, n = 4) after saline injection.
Effect of propofol on protein expression of nitric oxide 
synthase during endotoxemia
LPS treatment (15 mg/kg) also induced differential effects
on protein expression of NOS isoforms in the heart, lung
or aorta. In the heart (Fig. 5), but not lung (Fig. 6) or aorta
(Fig. 7), expression of nNOS protein was significantlyJournal of Biomedical Science 2009, 16:8 http://www.jbiomedsci.com/content/16/1/8
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Time-course changes in MSAP or HR after systemic injection of Escherichia coli Figure 1
Time-course changes in MSAP or HR after systemic injection of Escherichia coli. lipopolysaccharide (LPS, 15 
mg/kg) or saline (n = 7) in rats that were maintained under propofol anesthesia (15 or 30 mg/kg/h; n = 7 or 8). 
Values are mean ± SEM, n = 7 or 8 animals per experimental groups. *P < 0.05 vs. propofol + saline group and #P < 0.05 vs. low 
dose (15 m/kg/h) propofol group at corresponding time points in the Scheffé multiple-range test. The data of propofol (30 mg/
kg/h) + saline group were not shown because they were similar to that of propofol (15 mg/kg/h) + saline group.
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Changes in tissue level of malondialdehyde (MDA) in the heart, lung or aorta at 1 or 4 h after systemic injection of LPS (15 mg/ kg) or saline in rats that were maintained under propofol anesthesia (15 or 30 mg/kg/h) Figure 2
Changes in tissue level of malondialdehyde (MDA) in the heart, lung or aorta at 1 or 4 h after systemic injec-
tion of LPS (15 mg/kg) or saline in rats that were maintained under propofol anesthesia (15 or 30 mg/kg/h). Val-
ues are mean ± SEM of quadruplicate analyses of samples from 4 animals per each experimental group. *P < 0.05 vs. saline 
group and #P < 0.05 vs. low dose (15 m/kg/h) propofol group at corresponding time points in the Scheffé multiple-range test. 
Basal indicates MDA level in the corresponding tissue prior to LPS injection. The same data prior to saline injection was not 
shown because they were similar to that of LPS groups.
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increased by LPS treatment in animals that were under
propofol anesthesia (15 or 30 mg/kg/h). The endotoxin,
on the other hand, induced an upregulation of iNOS
expression in all three organs during early and late phases
of endotoxemia (Figs. 5, 6, 7). The LPS-induced iNOS
upregulation in both phases of endotoxemia was signifi-
cantly attenuated in the heart (Fig. 5) or lung (Fig. 6) of
animals that received propofol anesthesia at 30 mg/kg/h.
The same anesthetic infusion only inhibited iNOS upreg-
ulation in the aorta during late stage endotoxemia (Fig. 7).
LPS treatment also induced eNOS upregulation in the
heart (Fig. 5) or lung (Fig. 6) during both phases of endo-
toxemia in animals that were maintained under propofol
anesthesia at 30 mg/kg/h. The endotoxin, on the other
hand, induced eNOS expression in the aorta of animals
that received propofol infusion at 15 mg/kg/h (Fig. 7).
Propofol alone, at either dose, did not affect basal expres-
sion of nNOS, iNOS or eNOS in the heart, lung or aorta
of animals that received saline injection (data not shown).
Effect of propofol on survival time and mortality after LPS 
treatment
Compared to low dose (15 mg/kg/h) propofol infusion,
survival time after LPS treatment (15 mg/kg) was signifi-
cantly longer in animals that were maintained under high
dose (30 mg/kg/h) propofol anesthesia (Fig. 8). Mortality
rate 8 h after endotoxin injection was 100% or 60%,
respectively, for animals under propofol anesthesia at 15
or 30 mg/kg/h. All animals that were under propofol
anesthesia (15 or 30 mg/kg/h) survived the entire 8-h
observation period after saline injection.
Discussion
Compelling evidence indicates that cardiovascular depres-
sion plays a pivotal role in pathological sequelae leading
to multiple organ failure and fatality during endotoxemia.
Both oxidative injury and overproduction of NO in cardi-
ovascular and pulmonary systems contribute to fatal car-
diovascular depression during endotoxemia [4-
7,11,12,16]. We provided novel evidence in the present
study to suggest that oxidative injury and NO may play a
differential role in LPS-induced cardiovascular depres-
sion. ROS is associated with both early and late stage;
whereas NO is engaged primarily in late stage cardiovas-
cular depression. We further revealed that propofol infu-
sion may protect against fatal cardiovascular depression
during endotoxemia by attenuating the late stage NO
surge in the aorta, possibly via inhibition of iNOS upreg-
ulation by the endotoxin.
Diverse molecular mechanisms of cellular damage by the
endotoxin contribute to cardiovascular depression during
sepsis, of which overt production of NO and oxidative
injury to cardiovascular and pulmanory organs are of
praticular importance [6-8]. Although a vast amount of
evidence supports the pivatol roles of NO and ROS in
pathophysiology of endotoxemia, relative contribution of
these molecules in various organs during different stages
of cardiovascular depression has not been fully defined.
As such, one major contribution of the present study is to
demonstrate a differential association of oxidative tissue
injury and NO surge in LPS-induced cardiovascular
depression. In consistent to our previous findings [26,27],
LPS (15 mg/kg, i.v.) induces a biphasic cardiovascular
depression during endotoxemia. The early hypotension
Change in oxidative burst ratio of polymorphonuclear leuko- cytes (PMN) or lymphocytes at 1 or 4 h after systemic injec- tion of LPS (15 mg/kg) or saline in rats that were maintained  under propofol anesthesia (15 or 30 mg/kg/h) Figure 3
Change in oxidative burst ratio of polymorphonu-
clear leukocytes (PMN) or lymphocytes at 1 or 4 h 
after systemic injection of LPS (15 mg/kg) or saline in 
rats that were maintained under propofol anesthesia 
(15 or 30 mg/kg/h). Values are mean ± SEM of quadrupli-
cate analyses of samples from 4 animals per each experimen-
tal group. *P < 0.05 vs. saline group and #P < 0.05 vs. low 
dose (15 m/kg/h) propofol group at corresponding time 
points in the Scheffé multiple-range test. Basal indicates oxi-
dative burst ratio in the corresponding tissue prior to LPS 
injection. The same data prior to saline injection was not 
shown because they were similar to that of LPS groups.
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appeared immediately and lasted for approximately 1 h
after LPS injection and the late hypotension commenced
3 h after the endotoxin injection. In the heart, lung and
aorta, an abrupt increase in lipid peroxidation, our exper-
imental index of oxidative tissue injury, was detected in
early stage and sustained during late stage cardiovascular
depression. LPS injection, on the other hand, induced a
gradual increase in tissue nitrite and nitrate level in the
same organs that peaked during late stage endotoxemia.
Intriguingly, whereas the heart (maximal increase in MDA
production: 315 ± 18%, n = 4) and lung (maximal
increase in MDA production: 247 ± 23%, n = 4) are more
vulnerable than the aorta (maximal increase in MDA pro-
duction: 189 ± 17%, n = 4) to oxidative injury by the
endotoxin (cf. Fig. 2); NO production induced by LPS is
profoundly augmented in the aorta (maximal increase in
NOx level: 587 ± 45%, n = 4) than the heart (maximal
increase in NOx level: 329 ± 31%, n = 4) or the lung (max-
imal increase in NOx level: 436 ± 39%, n = 4) (cf. Fig. 4).
Together these results suggest that ROS and NO may dif-
ferentially mediate the deleterious effects on different car-
diovascular and pulmonary organs during different stages
of endotoxemia. In support of this suggestion, oxidative
stress of an increase tissue level of O2
￿- is greater in the
lung than aorta during early and late stage endotoxemia
induced by a cecal ligation and puncture [29]. A gradual
increase in plasma [30] or myocardial [31] concentration
of nitrates/nitrites was evident during late stage endotox-
emia. Pathologically, ROS production in the lung impairs
pulmonary vascular function early in the course of endo-
toxemia [32]. A sustained oxidative damage to the aorta is
involved in hypotension [23,29] and endothelial dysfunc-
tion [33,34] during late stage endotoxemia. In addition,
early and delayed production of O2
￿- via activation of the
NADPH oxidase mediates myocardial depression in LPS-
treated heart [35]. Vascular hyporeactivity to vasoactive
compound [23], delayed hypotension [29] and inflam-
mation of lung tissue [36,37], on the other hand, are
attributed to overproduction of NO during late stage of
endotoxemia.
Patients with endotoxemia often require drugs for seda-
tion and analgesia in the intensive care units. Several anes-
thetics, such as ketamine [38], dexmedetomidine [39] and
propofol [39,40], have been used in patients with septic
shock for these purposes. Whether propofol exerts protec-
tion against cardiovascular depression during endotox-
emia, however, is still debatable. In animal model of
sepsis, propofol has been shown to exert protection
against [41], no significant effect [24,36] or even aggrava-
tion [36] on cardiovascular depression during endotox-
emia. In the present study we demonstrate that propofol
exerted a dose-dependent differential protection against
cardiovascular depression during different stage of endo-
toxemia. During early stage endotoxemia, there was no
apparent difference in cardiovascular response to the
endotoxin in rats subjected to low (15 mg/kg) or high (30
mg/kg) dose propofol infusion. High dose propofol, on
the other hand, ameliorated cardiovascular depression
Changes in tissue level of nitrite and nitrate (NOx) in the  heart, lung or aorta at 1 or 4 h after systemic injection of LPS  (15 mg/kg) or saline in rats that were maintained under pro- pofol anesthesia (15 or 30 mg/kg/h) Figure 4
Changes in tissue level of nitrite and nitrate (NOx) in 
the heart, lung or aorta at 1 or 4 h after systemic 
injection of LPS (15 mg/kg) or saline in rats that were 
maintained under propofol anesthesia (15 or 30 mg/
kg/h). Values are mean ± SEM of quadruplicate analyses of 
samples from 4 animals per each experimental group. *P < 
0.05 vs. saline group and #P < 0.05 vs. low dose (15 m/kg/h) 
propofol group at corresponding time points in the Scheffé 
multiple-range test. Basal indicates NOx content in the cor-
responding tissue prior to LPS injection. The same data prior 
to saline injection was not shown because they were similar 
to that of LPS groups.
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during late stage endotoxemia. It was reported that the
biphasic cardiovascular responses to endotoxemia were
comparable in endotoxemic rats that received propofol
infusion at 5, 10, or 15 mg/kg [22,24,36]. Although we
did not estimate plasma concentration of propofol, the
reported mean blood propofol concentration after infu-
sion of propofol at 10, 15 or 60 mg/kg into rats was 4.2 ±
0.4 μg/ml [24], 8.2 ± 1.9 μg/ml [36] or 12.4 ± 0.8 μg/ml
[42], respectively. These plasma concentrations exceed the
propofol plasma concentration required to produce
anesthesia [43,44]. In this regard, the LPS-evoked cardio-
vascular depression was more severe in animals supple-
mented with pentobarbital sodium, which provided
satisfactory anesthesia similar to that by propofol.
Together these results suggest that the anesthetic effect of
propofol do not contribute primarily to cardiovascular
protection during endotoxemia and that a much higher
plasma concentration of propofol may need to exert car-
diovascular protection during endotoxemia. We realize
that discrepancy on cardiovascular protective effect of pro-
pofol on endotoxemia may also depend on animal spe-
cies (rodent, porcine, or rabbit) and animal models (cecal
ligation and puncture, LPS injection or) of endotoxemia,
as well as routes (subcutaneous, intraperitoneal, intrave-
nous) and regimens (pre- or post-LPS treatment) of drug
application.
Our results indicate that inhibition of late stage NO surge
in the aorta by propofol may underlie protection against
fatal cardiovascular depression during endotoxemia by
the anesthetic. Overproduction of NO via activation of
iNOS contributes to fatal cardiovascular depression and
mortality during late stage endotoxemia [45,46]. Propofol
at dose (30 mg/kg/h) that significantly attenuated the late
stage NO surge in the aorta at 4 and 6 h after LPS injection
also ameliorated cardiovascular depression during the
same stage of endotoxemia. A lack of effect to reverse LPS-
induced NO production in the heart, lung or aorta during
early stage endotoxemia, alongside an insignificant effect
of propofol on hemodynamic suppression during the
same stage of endotoxemia provide further support to the
suggestion. Moreover, low dose (15 mg/kg/h) propofol
that did not affect the LPS-induced early or late NO surge
also did not protect against cardiovascular depression dur-
ing early and late stage of endotoxemia. Although plasma
level of NOx was not measured in the present study, it was
reported that LPS causes at least 3 fold increase in plasma
NOx levels during the first 6 h after the endotoxin, and
propofol infusion significantly decreases plasma concen-
tration of NOx [24,47]. Our results also imply that the
anti-oxidant effect of propofol may not play an active role
in its cardiovascular protective effect during endotoxemia.
We found that although suppressing significantly the LPS-
induced lipid peroxidation in the heart, lung and aorta, as
well as ROS production in the PMN of the blood during
early stage endotoxemia, high dose propofol did not affect
the cardiovascular depression during the same stages of
endotoxemia. Moreover, suppression of ROS production
in the same organs by high dose propofol actually blunted
at 6 h after LPS injection during which protection of car-
diovascular depression occurred. Together these results
suggest that propofol may exert protection against late
stage fatal cardiovascular depression primarily by suppres-
Representative Western blots of neuronal nitric oxide syn- thase (nNOS), inducible NOS (iNOS) or endothelial NOS  (eNOS) (insets) or densitometric analysis in amount of pro- tein relative to α-tubulin from the heart at 1 or 4 h after sys- temic injection of LPS (15 mg/kg) in rats that were  maintained under propofol anesthesia (15 or 30 mg/kg/h) Figure 5
Representative Western blots of neuronal nitric 
oxide synthase (nNOS), inducible NOS (iNOS) or 
endothelial NOS (eNOS) (insets) or densitometric 
analysis in amount of protein relative to α-tubulin 
from the heart at 1 or 4 h after systemic injection of 
LPS (15 mg/kg) in rats that were maintained under 
propofol anesthesia (15 or 30 mg/kg/h). Values are 
mean ± SEM of quadruplicate analyses of samples from 4 ani-
mals per each experimental group. *P < 0.05 vs. basal expres-
sion and #P < 0.05 vs. low dose (15 m/kg/h) propofol group 
at corresponding time points in the Scheffé multiple-range 
test. Basal indicates expression of nNOS, iNOS or eNOS in 
the heart of the control groups at 30 min after propofol infu-
sion.
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sion of NO surge, although its anti-oxidant effect during
late stage endotoxemia could not be excluded.
Of the three NOS isoforms, our results demonstrated that
inhibition of LPS-induced iNOS upregulation by high
dose propofol may underlie the reduction in NO surge in
the aorta during late stage endotoxemia. It is well docu-
mented that iNOS-derived NO in the heart [48], lung [37]
and aorta [45] contributes respectively to myocardial dys-
function, acute lung injury and systemic hypotension
associated with endotoxemia. Inhibition of iNOS activity
or iNOS induction, on the other hand, attenuates the
delayed circulatory failure during endotoxemia [46]. Pro-
pofol has been reported to inhibit the induced iNOS
expression by endotoxin [49]. In the present study we
found that only in late stage endotoxemia there was a
close association between inhibitions of LPS-induced
iNOS upregulation, reduction in plasma NOx levels in the
aorta with amelioration of cardiovascular depression by
high dose propofol. It is interesting to note that inhibition
by propofol in the LPS-induced iNOS upregulation in the
heart or lung was not accompanied by attenuation in NO
surge during early and late endotoxemia. These results
were interpreted to suggest that iNOS might not contrib-
ute significantly to the increased NO production in the
heart and lung by LPS. In this regard, in murine sepsis-
induced acute lung injury, pulmonary oxidant stress is
completely iNOS dependent and is associated with tyro-
sine nitration [50]. The iNOS also mediates the nitrosa-
tive/oxidative damage and cardiac mitochondrial
dysfunction that occurs during endotoxemia [51]. Alter-
natively, our finding of the insignificant change in LPS-
induced NO surge in the heart or lung during endotox-
emia might be the consequences to the upregulations of
eNOS expression by high dose propofol.
In contrast to iNOS, a potential role for eNOS in cardio-
vascular depression during endotoxemia is controversial.
The LPS-induced increase in plasma level of nitrite and
nitrate was reported to be identical [52] or reduced [47] in
eNOS-/- knockout mice. Moreover, mice overexpressing
eNOS transgene generate similar levels of plasma nitrite
and nitrate to control animals in response to LPS [53].
Conflict results also exist in LPS-induced cardiovascular
depression and fatality, varying from no significant differ-
ence [52] to resistance [47,53,54] to endotoxemic shock
in eNOS-/- knockout mice. In the present study we found
that eNOS expressions were upregulated in the heart and
lung during early and late stage endotoxemia in rats sub-
jected to high dose propofol infusion. Since iNOS may
inhibit eNOS expression during endotoxemia [55], we
speculate that eNOS upregulations in these organs might
be a compensatory change to inhibition of the LPS-
induced iNOS expression during endotoxemia by high
dose propofol. Propofol inhibits the iNOS induction via
suppression of NF-κB nuclear translocation [56]. Induc-
tion of eNOS transcript is regulated by PI3K/Akt-depend-
ent pathway in endothelial cells [57]. Whether these
mechanisms account for the differential effects of propo-
fol on iNOS and eNOS expression during endotoxemia,
however, await further investigation. We also fund in the
Representative Western blots of nNOS, iNOS or eNOS  (insets) or densitometric analysis in amount of protein rela- tive to α-tubulin from the lung at 1 or 4 h after systemic  injection of LPS (15 mg/kg) in rats that were maintained  under propofol anesthesia (15 or 30 mg/kg/h) Figure 6
Representative Western blots of nNOS, iNOS or 
eNOS (insets) or densitometric analysis in amount of 
protein relative to α-tubulin from the lung at 1 or 4 h 
after systemic injection of LPS (15 mg/kg) in rats that 
were maintained under propofol anesthesia (15 or 30 
mg/kg/h). Values are mean ± SEM of quadruplicate analyses 
of samples from 4 animals per each experimental group. *P < 
0.05 vs. basal expression and #P < 0.05 vs. low dose (15 m/
kg/h) propofol group at corresponding time points in the 
Scheffé multiple-range test. Basal indicates expression of 
nNOS, iNOS or eNOS in the lung of the control groups at 
30 min after propofol infusion.
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present study that high dose propofol resulted in eNOS
upregulation in the heart and lung, but not in the aorta,
during early and late stage endotoxemia. The underlying
mechanism of these discrepancies is not immediate clear.
Propofol has been demonstrated to exert various effects
on eNOS expression under different pathological condi-
tions. The eNOS expression is increased by propofol in
hydrogen peroxide-stimulated [58] but inhibited in LPS-
stimulated human umbilical vein endothelial cells [59].
Propofol, on the other hand, had no effect on testicular
endothelial cells during ischemia-reperfusion injury [49].
The role of nNOS in cardiovascular failure and mortality
of sepsis also remains highly elusive. In nNOS-/- knockout
mice, mortality is increased in sepsis, possibly by increas-
ing proinflammatory cytokine response and impairing
bacterial clearance [60]. In contrast, deletion of nNOS
prevents impaired vasodilation [61] and restores arteri-
olar vasoconstriction in sepsis [62]. Although we found in
the present study that nNOS expression in the heart was
significantly increased during early and late stage endo-
toxemia, this induced nNOS upregulation was, nonethe-
less, not affected by propofol infusion. Significance of
nNOS in cardiovascular depression during endotoxemia,
therefore, remains to be elucidated.
In addition to oxidative injury of cardiovascular and pul-
monary organs, we found significant increases in respira-
tory burst activity in the peripheral blood PMN and
lymphocytes during early and late stage endotoxemia. The
PMN and lymphocytes play central roles in LPS-induced
inflammatory response [7,44]. Reduced neutrophil and
lymphocyte function, as determined by the increase in res-
piratory burst activity, may therefore lead to persistence of
infection, resulting in the maintenance of septic shock,
multiple organ dysfunction and death [44]. Our results of
inhibition by high dose propofol in LPS-induced early
and late phases of oxidative burst of PMN are in consistent
to the previous reports [7,44], and suggest the beneficial
effect of propofol to endotoxemia. This inhibition, none-
theless, may not contribute significantly to cardiovascular
protection by high dose propofol. We found that despite
of protection on LPS-induced augmentation in PMN burst
reaction during early stage endotoxemia, high dose pro-
pofol did not protect against cardiovascular depression
during the same stage of endotoxemia. A differential pro-
tective effect of high dose propofol on oxidative burst in
PMN versus lymphocytes is intriguing. Since PMN is more
prone than lymphocytes to oxidative damage during
endotoxemia, these blood cells might also be more sensi-
tive to agents that protect against the oxidative burst.
We notice that the dose (15 or 30 mg/k/h) of propofol
used in the present study was higher than the reported
dose (5 or 10 mg/kg/h) on protection against LPS-
induced inflammatory response [19] or metabolic acido-
sis [44], but much lower than that (120 mg/kg/h) to
reduce susceptibility of the red blood cells to oxidative
damage [63]. High dose propofol has been reported to
evoke a direct cardiovascular suppression via inhibition of
protein kinase C-mediated contraction of vascular
Representative Western blots of nNOS, iNOS or eNOS  (insets) or densitometric analysis in amount of protein rela- tive to α-tubulin from the aorta at 1 or 4 h after systemic  injection of LPS (15 mg/kg) in rats that were maintained  under propofol anesthesia (15 or 30 mg/kg/h) Figure 7
Representative Western blots of nNOS, iNOS or 
eNOS (insets) or densitometric analysis in amount of 
protein relative to α-tubulin from the aorta at 1 or 4 
h after systemic injection of LPS (15 mg/kg) in rats 
that were maintained under propofol anesthesia (15 
or 30 mg/kg/h). Values are mean ± SEM of quadruplicate 
analyses of samples from 4 animals per each experimental 
group. *P < 0.05 vs. basal expression and #P < 0.05 vs. low 
dose (15 m/kg/h) propofol group at corresponding time 
points in the Scheffé multiple-range test. Basal indicates 
expression of nNOS, iNOS or eNOS in the aorta of the con-
trol groups at 30 min after propofol infusion.
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smooth muscles [23]. It is empirical to include animals
that received LPS injection only as the control. Since the
experimental endotoxemia model used in the present
study was induced under anesthetic condition, the LPS
alone group (without propofol anesthesia) does not fol-
low the ethical guideline for care and use of laboratory
animals. Nonetheless, we have included saline-treated
group to demonstrate that propofol alone did not affect
NOx, NOS expression, ROS production or basal hemody-
namics (cf. Figs. 1, 2, 3, 4). We therefore reasoned that the
protective effects by propofol were observed only under
endotoxemic condition. We also realize that the propofol
preparation used in this study contains lipid components
that may exert biological activity. This possibility, how-
ever, is deem unlikely since propofol infusion alone did
not affect NOx, NOS expression, PMN burst reaction or
hemodynamic parameters in saline-treated animals. In
addition, lipid component (intralipid) of propofol was
reported to evoke minimal effects on NO and ROS pro-
duction [23].
Conclusion
In conclusion, we have demonstrated that oxidative injury
and NO may play a differential role in LPS-induced cardi-
ovascular depression during endotoxemia. ROS is associ-
ated with both early and late stage; whereas NO is engaged
primarily in late stage cardiovascular depression. We fur-
ther revealed that propofol infusion may protect against
fatal cardiovascular depression during endotoxemia by
attenuating the late stage NO surge in the aorta, possibly
via inhibition of iNOS upregulation by the endotoxin.
These beneficial effects of propofol may contribute to the
higher survival rate of rats with endotoxemia.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
YCL conceived the study, carried out animal experiments,
performed biochemical analysis, collected experimental
data, performed the statistical analysis and interpretation
of data, and drafted the manuscript. AYWC participated in
experimental design and was involved in revising the
manuscript for important intellectual content. YCT partic-
ipated in experimental design and coordination, and was
involved in revising the manuscript for important intellec-
tual content. JYHC participated in experimental design,
interpretation of the data, involved in revising the manu-
script for important intellectual content and have given
final approval of the version to be published. All authors
read and approved the final manuscript.
Acknowledgements
This work was supported by research grants VGHKS93-09 from Kaohsiung 
Veteran General Hospital (L.Y.C.). Kaohsiung and NCKUH96-41 from 
National Cheng Kung University Medical College and Hospital (L.Y.C.), 
Tainan, Taiwan.
References
1. Hotchkiss RS, Karl IE: The pathophysiology and treatment of
sepsis.  N Engl J Med 2003, 348:138-150.
2. Stephens RC, Fidler K, Wilson P, Barclay GR, Mythen MG, Dixon GL,
Turner MW, Klein NJ, Peters MJ: Endotoxin immunity and the
development of the systemic inflammatory response syn-
drome in critically ill children.  Intensive Care Med 2006,
32:286-294.
3. Parrillo JE: Pathogenetic mechanisms of septic shock.  N Engl J
Med 1993, 328:1471-1477.
4. Vincent JL, De Backer D: Microvascular dysfunction as a cause
of organ dysfunction in severe sepsis.  Crit Care 2005, 9:S9-S12.
5. Abraham E, Singer M: Mechanisms of sepsis-induced organ dys-
function.  Crit Care Med 2007, 35:2408-2416.
6. Salvemini D, Cuzzocrea S: Oxidative stress in septic shock and
disseminated intravascular coagulation.  Free Radic Biol Med
2002, 33:1173-1185.
7. Azevedo LC, Janiszewski M, Soriano FG, Laurindo FR: Redox mech-
anisms of vascular cell dysfunction in sepsis.  Endocr Metab
Immune Disord Drug Targets 2006, 6:159-164.
8. Goldfarb RD, Cinel I: Inhaled nitric oxide therapy for sepsis:
more than just lung.  Crit Care Med 2007, 35:290-292.
9. Thiemermann C, Vane JR: Inhibition of nitric oxide synthesis
reduces the hypotension induced by bacterial lipopolysac-
charide in the rat in vivo.  Eur J Pharmacol 1990, 182:591-595.
10. Thiemermann C, Ruetten H, Wu CC, Van JR: The multiple organ
dysfunction syndrome caused by endotoxin in the rat: atten-
uation of liver dysfunction by inhibitors of nitric oxide syn-
thase.  Br J Pharmacol 1995, 116:2845-2851.
11. Chen HI, Chang HR, Wu CY, Kao SJ, Wang D, Hsieh NK, Hsu YH:
Nitric oxide in the cardiovascular and pulmonary circulation
– a brief review of literatures and historical landmarks.  Chin
J Physiol 2007, 50:43-50.
Changes in survival time during 8-h observation period after  systemic injection of LPS (15 mg/kg) or saline (n = 8) in rats  that were maintained under propofol anesthesia (15 or 30  mg/kg/h; n = 9 or 8) Figure 8
Changes in survival time during 8-h observation 
period after systemic injection of LPS (15 mg/kg) or 
saline (n = 8) in rats that were maintained under pro-
pofol anesthesia (15 or 30 mg/kg/h; n = 9 or 8). Values 
are mean ± SEM, n = 8 or 9 animals per experimental groups. 
*P < 0.05 vs. propofol group and #P < 0.05 vs. low dose pro-
pofol (15 m/kg/h) group in one way ANOVA.
S
U
R
V
I
V
A
L
 
T
I
M
E
 
(
m
i
n
)
0
60
120
180
240
300
360
420
480
540
Propofol (15 mg/kg/h)      
Propofol (30 mg/kg/h)      
LPS (15 mg/kg)                
*
#Journal of Biomedical Science 2009, 16:8 http://www.jbiomedsci.com/content/16/1/8
Page 13 of 14
(page number not for citation purposes)
12. Callahan LA, Nethery D, Stofan D, DiMarco A, Supinski G: Free rad-
ical-induced contractile protein dysfunction in endotoxin-
induced sepsis.  Am J Respir Cell Mol Biol 2001, 24:210-217.
13. Cuzzocrea S, Riley DP, Caputi AP, Salveminin D: Antioxidant ther-
apy: a new pharmacological approach in shock, inflamma-
tion, and ischemia/reperfusion injury.  Pharmacol Rev 2001,
53(1):135-159.
14. Cerwinka WH, Cooper D, Krieglstein CF, Ross CR, McCord JM,
Granger DN: Superoxide mediates endotoxin-induced plate-
let-endothelial cell adhesion in intestinal venules.  Am J Physiol
Heart Circ Physiol 2003, 284:H535-H541.
15. Fujimi S, Ogura H, Tanaka H, Koh T, Hosotsubo H, Nakamori Y,
Kuwagata Y, Shimazu T, Sugimoto H: Activated polymorphonu-
clear leukocytes enhance production of leukocyte micropar-
ticles with increased adhesion molecules in patients with
sepsis.  J Trauma 2002, 52:443-448.
16. Lin SL, Lee YM, Chang HY, Cheng YW, Yen MH: Effects of naltrex-
one on lipopolysaccharide-induced sepsis in rats.  J Biomed Sci
2005, 12:431-440.
17. Hsu DZ, Su SB, Chien SP, Chiang PJ, Li YH, Lo YJ, Liu MY: Effect of
sesame oil on oxidative-stress-associated renal injury in
endotoxemic rats: involvement of nitric oxide and proin-
flammatory cytokines.  Shock 2005, 24:276-280.
18. Bryson HM, Fulton BR, Faulds D: Propofol: An update of its use
in anesthesia and conscious sedation.  Drugs 1995, 50:513-519.
19. Chen RM, Chen TG, Chen TL, Lin LL, Chang CC, Chang HC, Wu CH:
Anti-inflammatory and antioxidative effects of propofol on
lipopolysaccharide-activated macrophages.  Ann N Y Acad Sci
2005, 1042:262-271.
20. Kanakura H, Taniguchi T: The antiinflammatory effects of pro-
pofol in endotoxemic rats during moderate and mild hypo-
thermia.  J Anesth 2007, 21:354-360.
21. Kwak SH, Choi JI, Park JT: Effects of propofol on endotoxin-
induced acute lung injury in rabbit.  J Korean Med Sci 2004,
19:55-61.
22. Chen HI, Hsieh NK, Kao SJ, Su CF: Protective effects of propofol
on acute lung injury induced by oleic acid in conscious rats.
Crit Care Med 2008, 36:1214-1221.
23. Yu HP, Lui PW, Hwang TL, Yen CH, Lau YT: Propofol improves
endothelial dysfunction and attenuates vascular superoxide
production in septic rats.  Crit Care Med 2006, 34:453-460.
24. Tsao CM, Ho ST, Chen A, Wang JJ, Tsai SK, Wu CC: Propofol
ameliorates liver dysfunction and inhibits aortic superoxide
level in conscious rats with endotoxic shock.  Eur J Pharmacol
2003, 477:183-193.
25. Redl H, Bahrami S, Schlag G, Traber DL: Clinical detection of LPS
and animal models of endotoxemia.  Immunobiology 1993,
187:330-345.
26. Poon YY, Chang AY, Chan SH: Differential contribution of N-
methyl-D-aspartate and non-N-methyl-D-aspartate recep-
tors in the intermediolateral cell column of the thoracic spi-
nal cord to sympathetic vasomotor tone during
experimental endotoxemia in the rat.  Shock 2006, 26:372-378.
27. Chang AY, Chan JY, Chou JL, Li FC, Dai KY, Chan SH: Heat shock
protein 60 in rostral ventrolateral medulla reduces cardio-
vascular fatality during endotoxaemia in the rat.  J Physiol 2006,
574:547-564.
28. Kahraman S, Kilinç K, Dal D, Erdem K: Propofol attenuates for-
mation of lipid peroxides in tourniquet-induced ischaemia-
reperfusion injury.  Br J Anaesth 1997, 78:279-281.
29. Liaw WJ, Chen TH, Lai ZZ, Chen SJ, Chan A, Tzao C, Wu JY, Wu CC:
Effect of a membrane-permeable radical scavenger, tempol,
on intraperitoneal sepsis-induced organ injury in rats.  Shock
2005, 23:88-96.
30. Payabvash S, Ghahremani MH, Goliaei A, Mandegary A, Shafaroodi H,
Amanlou M, Dhpour AR: Nitric oxide modulates glutathione
synthesis during endotoxemia.  Free Radic Biol Med 2006,
41:1817-1828.
31. Jozehowicz E, Brisson H, Rozenberg S, Mebazaa A, Gele P, Callebert
J, Lebuffe G, Vallet B, Vordet R, Tavernier B: Activation of peroxi-
some proliferator-activated receptor-alpha by fenofibrate
prevents myocardial dysfunction during endotoxemia in
rats.  Crit Care Med 2007, 35:856-863.
32. Baboolal HA, Tchinose F, Ullrich R, Kawai N, Bloch KD, Zapol WM:
Reactive oxygen species scavengers attenuate endotoxin-
induced impairment of hypoxic pulmonary vasoconstriction
in mice.  Anesthesiology 2002, 97:1227-1233.
33. Virdis A, Colucci R, Fornai M, Balandizzi C, Duranti E, Pinto S, Ber-
nardini N, Segnani C, Antonioli L, Taddei S, Salvetti A, Del Tacca M:
Cycloxygenase-2 inhibition improves vascular endothelial
dysfunction in a rat model of endotoxic shock: role of induc-
ible nitric-oxide synthase and oxidative stress.  J Pharmacol Exp
Ther 2005, 312:945-953.
34. Wu F, Schuster DP, Tyml K, Wilson JX: Ascorbate inhibits
NADPH oxidase subunit p47phox expression in microvascu-
lar endothelial cells.  Free Radic Biol Med 2007, 42:124-131.
35. Peng T, Lu X, Feng Q: Pivotal role of gp91phox-containing oxi-
dase in lipopolysaccharide-induced tumor necrosis factor-
alpha expression and myocardial depression.  Circulation 2005,
111:1637-1644.
36. Takao Y, Mikawa K, Nishina K, Obara H: Attenuation of acute
lung injury with propofol in endotoxemia.  Anesth Analg 2005,
100:810-816.
37. Zaedi S, Jesmin S, Maeda S, Shimojo N, Yamaguchi I, Goto K, Miyauchi
T: Alterations in gene expressions encoding preproET-1 and
NOS in pulmonary tissue in endotoxemic rats.  Exp Bio Med
2006, 231:992-996.
38. Westphal M, Traber DL: Ketamine in critical illness: another
no-NO agent?  Crit Care Med 2005, 33:1162-1163.
39. Kadoi Y, Saito S, Kawauchi C, Hinohara H, Kunimoto F: Compara-
tive effects of propofol vs dexmedetomidine on cerebrovas-
cular carbon dioxide reactivity in patients with septic shock.
Br J Anaesth 2008, 100:224-229.
40. Marik PE, Gary Z: Therapeutic sedation: Has its time come?
Crit Care Med 2002, 30:949-952.
41. Takemoto Y: Dose effects of propofol on hemodynamic and
cytokine responses to endotoxemia in rats.  J Anesth 2005,
19:40-44.
42. Logginidou HG, Li BH, Li DP, Lohmann JS, Schuler HG, DiVittore NA,
Kreiser S, Cronin AJ: Propofol suppresses the cortical somato-
sensory evoked potential in rats.  Anesth Analg 2003,
97:1784-1788.
43. Vuyk J, Mertens MJ, Olofsen E, Burm AG, Bovill JG: Propofol
anesthesia and rational opioid selection: determination of
optimal EC50-EC95 propofol-opioid concentrations that
assure adequate anesthesia and a rapid return of conscious-
ness.  Anesthesiology 1997, 87:1549-1562.
44. Taniguchi T, Yamamoto K, Ohmoto N, Ohta K, Kobayashi T: Effects
of propofol on hemodynamic and inflammatory responses to
endotoxemia in rats.  Crit Care Med 2000, 28:1101-1106.
45. Matsuda N, Hattori Y, Zhang XH, Fukui H, Kemmotsu O, Gando S:
Contractions to histamine in pulmonary and mesenteric
arteries from endotoxemic rabbits: modulation by vascular
expression of inducible nitric-oxide synthase and histamine
H1-receptors.  J Pharmacol Exp Ther 2003, 307:175-181.
46. Wu CC, Chen SJ, Szabo C, Thiemermann C, Vane JR: Aminoguani-
dine attenuates the delayed circulatory failure and improves
survival in rodent models of endotoxic shock.  Br J Pharmacol
1995, 114:1666-1672.
47. Connelly L, Madhani M, Hobbs AJ: Resistance to endotoxic shock
in endothelial nitric-oxide synthase (eNOS) knock-out mice.
J Biol Chem 2005, 280:10040-10046.
48. Ullrich R, Scherrer-Crosbie M, Bloch KD, Ichinose F, Nakajima H,
Picard MH, Xapal WM, Quezado ZM: Congenital deficiency of
nitric oxide synthase 2 protects against endotoxin-induced
myocardial dysfunction in mice.  Circulation 2000,
102:1440-1446.
49. Yagmurdur H, Ayyildiz A, Karaguzel E, Akgul T, Ustun H, Germiya-
noglu C: Propofol reduces nitric oxide-induced apoptosis in
testicular ischemia-reperfusion injury by downregulating the
expression of inducible nitric oxide synthase.  Acta Anaesthesiol
Scand 2008, 52:350-357.
50. Razavi HM, Wang L, Weicker S, Quinlan GJ, Mumby S, McCormack
DG, Mehta S: Pulmonary oxidant stress in murine sepsis is due
to inflammatory cell nitric oxide.  Crit Care Med 2005,
33:1333-1339.
51. Escames G, Lopez LC, Ortiz F, Lopez A, Garcia JA, Ros E, Acuna-Cas-
troviejo D: Attenuation of cardiac mitochondrial dysfunction
by melatonin in septic mice.  FEBS J 2007, 274:2135-2147.
52. Shesely EG, Maeda N, Kim HS, Desai KM, Krege JH, Laubach VE,
Sherman PA, Sessa WC, Smithies O: Elevated blood pressures inPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Biomedical Science 2009, 16:8 http://www.jbiomedsci.com/content/16/1/8
Page 14 of 14
(page number not for citation purposes)
mice lacking endothelial nitric oxide synthase.  Proc Natl Acad
Sci USA 1996, 93:13176-13181.
53. Yamashita T, Kawashima S, Ohashi Y, Ozaki M, Ueyama T, Ishida T,
Inoue N, Hirata K, Akita H, Yokoyama M: Resistance to endotoxin
shock in transgenic mice overexpressing endothelial nitric
oxide synthase.  Circulation 2000, 101:931-937.
54. Ichinose F, Buys ES, Neilan TG, Furutani EM, Morgan JG, Jassal DS,
Graveline AR, Searles RJ, Lim CC, Kaneki M, Picard MH, Scherrer-
Crosbie M, Janssens S, Liao R, Bloch KD: Cardiomyocyte-specific
overexpression of nitric oxide synthase 3 prevents myocar-
dial dysfunction in murine models of septic shock.  Circ Res
2007, 100:130-139.
55. Chauhan SD, Seggara G, Vo PA, Macallister RJ, Hobbs AJ, Ahluwalia
A: Protection against lipopolysaccharide-induced endothelial
dysfunction in resistance and conduit vasculature of iNOS
knockout mice.  FASEB J 2003, 17:773-775.
56. Brasil LJ, San-Miguel B, Kretzmann NA, Amaral JL, Zettler CG, Mar-
roni N, González-Gallego J, Tunon MJ: Halothane induces oxida-
tive stress and NF-κB activation in rat liver: protective effect
of propofol.  Toxicology 2006, 227:53-61.
57. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM:
Activation of nitric oxide synthase in endothelial cells by
Akt-dependent phosphorylation.  Nature 1999, 399:601-605.
58. Wang B, Luo T, Chen D, Ansley DM: Propofol reduces apoptosis
and up-regulates endothelial nitric oxide synthase protein
expression in hydrogen peroxide-stimulated human umbili-
cal vein endothelial cells.  Anesth Analg 2007, 105:1027-1033.
59. Peng Z, Luo M, Ye S, Critchley LA, Joynt GM, Ho AM, Yao S: Anti-
oxidative and anti-endotoxin effects of propofol on endothe-
lial cells.  Chin Med J 2003, 116:731-735.
60. Cui X, Besch V, Khaibullina A, Hergen A, Quezado M, Eichacker P,
Quezado ZM: Neuronal nitric oxide synthase deficiency
decreases survival in bacterial peritonitis and sepsis.  Intensive
Care Med 2007, 33:1993-2003.
61. Lidington D, Li F, Tyml K: Deletion of neuronal NOS prevents
impaired vasodilation in septic mouse skeletal muscle.  Cardi-
ovasc Res 2007, 74:151-158.
62. McKinnon RL, Lidington D, Tyml K: Ascorbate inhibits reduced
arteriolar conducted vasoconstriction in septic mouse cre-
master muscle.  Microcirculation 2007, 14:697-707.
63. Runzer TD, Ansley DM, Godin DV, Chambers GK: Tissue antioxi-
dant capacity during anesthesia: propofol enhances in vivo
red cell and tissue antioxidant capacity in a rat model.  Anesth
Analg 2002, 94:89-93.